This statistic shows the sales value of outpatient prescription drugs for benign prostatic hyperplasia (BPH) in South Korea in 2016, by age group. In 2016, the BPH medication sales for patients aged between 70 and 79 years amounted to over 92 billion South Korean won.
Sales value of outpatient prescription drugs for benign prostatic hyperplasia (BPH) in South Korea in 2016, by age group (in billion South Korean won)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
9
- Premium Statistic Most common prescription drugs for prostatic hyperplasia South Korea 2016
- Premium Statistic Drugs for Alzheimer's disease sales in South Korea 2011-2016
- Premium Statistic Annual average cost of orphan drugs per patient 2014-2018
- Premium Statistic Anti-diabetics estimated market size in South Korea 2014-2020
- Premium Statistic Anti-cancer drugs estimated market size in South Korea 2014-2020
- Basic Statistic Total public drug program spending in Canada by therapy 2022
- Basic Statistic Alprazolam out of pocket cost in the U.S. 2004-2021
- Basic Statistic Esomeprazole prescriptions number U.S. 2007-2021
- Basic Statistic Rosuvastatin out-of-pocket cost U.S. 2004-2021
About the region
10
- Premium Statistic Prostatic hyperplasia patient number in South Korea 2010-2020
- Premium Statistic Alzheimer's patient number South Korea 2013-2024
- Premium Statistic Cardiovascular disease drugs estimated market size in South Korea 2014-2020
- Premium Statistic Cholesterol drugs estimated market size in South Korea 2014-2020
- Premium Statistic Sales revenue of JW Pharmaceutical 2014-2022
- Premium Statistic Operating profit of JW Pharmaceutical 2014-2022
- Premium Statistic R&D spending of JW Pharmaceutical South Korea 2014-2022
- Premium Statistic R&D spending ratio of JW Pharmaceutical South Korea 2014-2022
- Premium Statistic Sales revenue distribution of JW Pharmaceutical South Korea 2022, by channel
- Premium Statistic Sales revenue Celltrion 2013-2022
Selected statistics
6
- Premium Statistic Expenditure worldwide on diabetes by market 2013-2018
- Premium Statistic Chinese insulin market distribution: leading companies 2011
- Premium Statistic U.S. insulin market distribution: leading companies 2011
- Basic Statistic AstraZeneca's revenue from top product Pulmicort 2006-2023
- Premium Statistic Medicinal market growth worldwide including rebates 2009-2018
- Premium Statistic Standard Unit medicine use per capita in the U.S. 2007-2011
Other regions
10
- Basic Statistic Alzheimer and other dementia caregivers' unpaid care in the U.S. 2011-2023
- Basic Statistic Export value of medicinal and pharmaceutical products in Denmark 2010-2023
- Basic Statistic Rate of return on biopharma R&D late stage pipeline 2013-2022
- Basic Statistic Number of users of prescription drugs in Norway by ATC main group 2021
- Premium Statistic Number of applications for clinical trials in Sweden 2014-2021, by sponsor
- Premium Statistic Number of persons misusing select Rx drug types in U.S. 2017, by age
- Basic Statistic Quarterly medical cannabis oil products sold in Canada 2016-2019
- Premium Statistic Import value of pharmaceutical products in Poland 2011-2022
- Premium Statistic Mexico: pharmaceutical expenditure 2012-2018
- Basic Statistic Alaska's medical cannabis spending 2018-2024
Related statistics
10
- Premium Statistic Frequency of food service use alone in South Korea 2019, by age group
- Premium Statistic Market share of Celltrion's Remsima in Europe Q1 2015-Q2 2018
- Premium Statistic Market share of Celltrion's Truxima in Europe Q2 2017-Q2 2018
- Premium Statistic Importance of a TV in South Korea 2017, by age group
- Premium Statistic Parenteral nutrition company market share in South Korea 2015
- Premium Statistic Number of medical tourism patients in South Korea for cancer treatment 2009-2013
- Premium Statistic Sales revenue of GC Pharma 2015-2023
- Premium Statistic Revenue of Chong Kun Dang 2015-2023
- Premium Statistic Sales revenue Samsung Biologics 2015-2023
- Premium Statistic Biopharmaceutical production value in South Korea 2012-2022
Further related statistics
9
- Global pharmaceutical pipeline by therapy area 2013-2017
- Merck & Co total assets 2009-2023
- CVS Health's total assets 2005-2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Alzheimer's amongst older people in 2050: impact of a 5-year delay in onset
- Projected costs of care for older U.S. Alzheimer sufferers 2010-2050
- Sanofi's total assets 2007-2023
- Merck & Co - expenditure on research and development 2006-2023
- Merck & Co cash dividends declared 2006-2023
Further Content: You might find this interesting as well
Statistics
- Global pharmaceutical pipeline by therapy area 2013-2017
- Merck & Co total assets 2009-2023
- CVS Health's total assets 2005-2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Alzheimer's amongst older people in 2050: impact of a 5-year delay in onset
- Projected costs of care for older U.S. Alzheimer sufferers 2010-2050
- Sanofi's total assets 2007-2023
- Merck & Co - expenditure on research and development 2006-2023
- Merck & Co cash dividends declared 2006-2023
KHIDI. (February 6, 2018). Sales value of outpatient prescription drugs for benign prostatic hyperplasia (BPH) in South Korea in 2016, by age group (in billion South Korean won) [Graph]. In Statista. Retrieved May 13, 2024, from https://www.statista.com/statistics/863824/south-korea-prostatic-hyperplasia-outpatient-prescription-drug-sales-by-age-group/
KHIDI. "Sales value of outpatient prescription drugs for benign prostatic hyperplasia (BPH) in South Korea in 2016, by age group (in billion South Korean won)." Chart. February 6, 2018. Statista. Accessed May 13, 2024. https://www.statista.com/statistics/863824/south-korea-prostatic-hyperplasia-outpatient-prescription-drug-sales-by-age-group/
KHIDI. (2018). Sales value of outpatient prescription drugs for benign prostatic hyperplasia (BPH) in South Korea in 2016, by age group (in billion South Korean won). Statista. Statista Inc.. Accessed: May 13, 2024. https://www.statista.com/statistics/863824/south-korea-prostatic-hyperplasia-outpatient-prescription-drug-sales-by-age-group/
KHIDI. "Sales Value of Outpatient Prescription Drugs for Benign Prostatic Hyperplasia (Bph) in South Korea in 2016, by Age Group (in Billion South Korean Won)." Statista, Statista Inc., 6 Feb 2018, https://www.statista.com/statistics/863824/south-korea-prostatic-hyperplasia-outpatient-prescription-drug-sales-by-age-group/
KHIDI, Sales value of outpatient prescription drugs for benign prostatic hyperplasia (BPH) in South Korea in 2016, by age group (in billion South Korean won) Statista, https://www.statista.com/statistics/863824/south-korea-prostatic-hyperplasia-outpatient-prescription-drug-sales-by-age-group/ (last visited May 13, 2024)
Sales value of outpatient prescription drugs for benign prostatic hyperplasia (BPH) in South Korea in 2016, by age group (in billion South Korean won) [Graph], KHIDI, February 6, 2018. [Online]. Available: https://www.statista.com/statistics/863824/south-korea-prostatic-hyperplasia-outpatient-prescription-drug-sales-by-age-group/